In 2022 and 2023, rising interest rates drove up the yields of low-risk fixed income investments like Treasury bills, bonds, and CDs, which made them more appealing than dividend stocks. But as interest rates decline, those fixed income yields are shrinking and driving more investors back toward higher-yielding dividend stocks.One of those stocks is Agree Realty (ADC 1.05%), which has gained about 14% during the past 12 months but still pays an attractive forward yield of 4.3%. Let's see if it's the right t ...

Agree Realty (ADC 1.05%) has been a popular stock in 2024, with a share price gain of more than 15%. That's roughly three times the return of the average real estate investment trust (REIT). Although Agree's dividend yield is above the REIT average at around 4% (versus the 3.7% average), it might be time to consider a value-conscious alternative. Here's the biggest option that you should be looking at today. There are a lot of reasons to like Agree RealtyAgree Realty is a very well-run net lease REIT (a net ...

Aadi Enters into Exclusive License for Three-Asset ADC Portfolio Developed through a Collaboration between WuXi Biologics and HANGZHOU DAC  Aadi Enters Agreement to Sell FYARRO® and Associated Infrastructure to KAKEN Pharmaceutical for $100M; Announces PIPE Financing of $100MCumulative Capital Expected to Fund Operations into Late 2028, Including Anticipated Clinical Data for the ADC PortfolioCo-Founder and Former CEO of ProfoundBio, Baiteng Zhao, Appointed to Aadi Board of DirectorsAadi to Hold Webcast and ...

Mersana Therapeutics (NASDAQ: MRSN ) is an early phase biotech that has faced challenges in recent years, having shelved several once-promising clinical candidates. In my first outing on the company, I suggested that theyI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitf ...

Dividend growth stocks aren't always the most exciting investments out there. They often aren't grabbing the headlines, and they aren't theFor some background on this monthly publication, here is my view on dividend growth stocks :Interested in more income ideas? Check out Cash Builder Opportunities, where we provide ideas about high-quality and reliable dividend growth ideas. These investments are designed to build growing income for investors. A special focus on investments that are leaders within their i ...

Contributing analyst to the iREIT+Hoya Capital investment group. The Dividend Collectuh is not a registered investment professional nor financial advisor and these articles should not be taken as financial advice. This is for educational purposes only and I encourage everyone to do their own due diligence. I'm a Navy veteran who enjoys dividend investing in quality blue-chip stocks, BDC's, and REITs. I am a buy-and-hold investor who prefers quality over quantity and plans to supplement his retirement income ...

Net lease real estate investment trust (REIT) Agree Realty (ADC 1.39%) has a 4.1% dividend yield. That yield is a little higher than the 3.7% average for the REIT sector, but below the 5.6% you could get from buying industry leading net lease REIT Realty Income. Is Agree Realty worth the premium price for investors looking to build seven-figure portfolios? Maybe.What is a net lease REIT?A net lease requires tenants to pay most property-level operating costs. Net lease assets are usually leased to a single t ...

This article is published by Terry Chrisomalis, who runs the Biotech Analysis Central pharmaceutical service on Seeking Alpha Marketplace. If you like what you read here and would like to subscribe to, I'm currently offering a two-week free trial period for subscribers to take advantage of. My service offers a deep-dive analysis of many pharmaceutical companies. The Biotech Analysis Central SA marketplace is $49 per month, but for those who sign up for the yearly plan will be able to take advantage of a 33. ...

-- EO-1022 is comprised of seribantumab, an anti-HER3 monoclonal antibody, and an MMAE payload –-- Following recently signed global license agreement with Synaffix, EO-1022 leverages the company's GlycoConnect® and HydraSpace® ADC technologies for glycan site-specific conjugation and SYNstatin E™ linker-payload --– Elevation Oncology expects to present EO-1022 preclinical data in 1H 2025 and to file an IND application in 2026 –BOSTON, Dec. 12, 2024 /PRNewswire/ -- Elevation Oncology, Inc. (Nasdaq: ELEV), an ...

Licensing agreement gives Elevation Oncology access to Synaffix's ADC technology for one program in combination with SYNstatin E™ Elevation Oncology nominates a novel HER3 ADC candidate EO-1022 leveraging its antibody as well as Synaffix's proprietary ADC development technologiesAMSTERDAM, Dec. 12, 2024 /PRNewswire/ -- Synaffix B.V., a Lonza company (SIX: LONN) focused on commercializing its clinical-stage platform technology for the development of antibody-drug conjugates (ADCs) with best-in-class therape ...